Retatrutide, a experimental dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is showing promising data in initial human trials . Current research implies https://bookmarklogin.com/story21513630/retatrutide-emerging-research-and-potential-clinical-applications